Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis

Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis

Background: This study investigates the potential predictors of nivolumab plus chemotherapy or multitarget tyrosine kinase inhibitor (TKI) treatment response in patients with recurrent hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).Methods: Patients with recurrent hepatitis B virus-r...

Full description

Bibliographic Details
Main Authors:	Chao Chen, Li An, Ying Cheng, Xianwen Luo, Zixiong Li, Xiufeng Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-08-01
Series:	Frontiers in Oncology
Subjects:	hepatocellular carcinoma hepatitis B virus nivolumab chemotherapy tyrosine kinase inhibitor programmed cell death protein 1
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2020.01404/full

Similar Items

MBP-11901 Inhibits Tumor Growth of Hepatocellular Carcinoma through Multitargeted Inhibition of Receptor Tyrosine Kinases
by: Chang, S.J, et al.
Published: (2022)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
by: Yuan-Hung Kuo, et al.
Published: (2021-05-01)

Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma
by: Tsai-Hung Yen, et al.
Published: (2020-07-01)

Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection
by: Pil Soo Sung, et al.
Published: (2020-06-01)

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
by: Lisha Mou, et al.
Published: (2021-10-01)

Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma
by: Satoshi Shiba, et al.
Published: (2012-09-01)

Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma
by: Shih-Hung Yang, et al.
Published: (2021-01-01)

Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma
by: Tsukasa Narukawa, et al.
Published: (2020-03-01)

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
by: Yi Yang, et al.
Published: (2020-02-01)

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma
by: Jeong Il Yu, et al.
Published: (2019-11-01)

The Roles of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma
by: Yide Huang, et al.
Published: (2018-03-01)

Successful treatment of recurrent metastatic nasopharyngeal carcinoma with nivolumab: a case report
by: Yu. M. Bychkov, et al.
Published: (2019-07-01)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
by: Cheol-Hyung Lee, et al.
Published: (2020-07-01)

Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience
by: Ouissam Al jarroudi, et al.
Published: (2021-04-01)

Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date
by: Tella SH, et al.
Published: (2019-11-01)

Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
by: Hayato Watanabe, et al.
Published: (2021-06-01)

Resensitization to Nivolumab after Intratumoral Chemotherapy in Recurrent Head and Neck Squamous Cell Cancer: A Report of 2 Cases
by: Aline Houessinon, et al.
Published: (2020-07-01)

Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2021-09-01)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
by: Huabin Hu, et al.
Published: (2020-09-01)

The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma
by: Yun Wang, et al.
Published: (2020-12-01)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019-01-01)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
by: Francesco Tovoli, et al.
Published: (2020-10-01)

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
by: Bin Wu, et al.
Published: (2018-11-01)

Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy
by: Sebastian Krammer, et al.
Published: (2019-11-01)

Immunotherapy for hepatocellular cancer: beginning and future perspectives
by: M. A. Kazantseva, et al.
Published: (2019-06-01)

Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab
by: Li Li, et al.
Published: (2017-03-01)

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
by: Jingjie Chen, et al.
Published: (2020-07-01)

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
by: Ayako Shiono, et al.
Published: (2019-04-01)

Nivolumab as the new standard of metastatic kidney cancer treatment
by: V. B. Matveev
Published: (2017-10-01)

Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment
by: Komugi Okeya, et al.
Published: (2020-07-01)

Successful rechallenge with cetuximab after progression with nivolumab for recurrent cervical lymph node metastasis from carcinoma of the tongue
by: Yasuyuki Asada, et al.
Published: (2021-07-01)

Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer
by: Yixin Zhou, et al.
Published: (2020-03-01)

Severe Pneumonitis after Nivolumab Treatment Accompanied by Acute Pulmonary Embolism in a Patient with Lung Adenocarcinoma
by: Ji-Ping Liao, et al.
Published: (2017-01-01)

A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy
by: Sooyeon Oh, et al.
Published: (2020-03-01)

Nivolumab-induced oral and cutaneous bullous pemphigoid: A case report
by: Sturque Julie, et al.
Published: (2019-01-01)

Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences
by: Ramazan Acar, et al.
Published: (2020-12-01)

Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro
by: Johanna Weiss, et al.
Published: (2014-12-01)

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
by: Saaya Yoshida, et al.
Published: (2019-10-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011-12-01)

Receptor tyrosine kinases and schistosome reproduction: new targets for chemotherapy
by: Marion eMorel, et al.
Published: (2014-07-01)